A phase I study of volasertib combined with afatinib, in advanced solid tumors
- 8 September 2015
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 76 (4) , 843-851
Abstract
To determine the maximum tolerated dose (MTD) of volasertib, a Polo-like kinase inhibitor, combined with afatinib, an oral irreversible ErbB family blocker, in patients with advanced solid tumors (NCT01206816; Study 1230.20).Keywords
This publication has 24 references indexed in Scilit:
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyBlood, 2014
- An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerCancer, 2013
- A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumoursEuropean Journal of Cancer, 2012
- Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLCClinical Cancer Research, 2011
- Multifaceted polo-like kinases: drug targets and antitargets for cancer therapyNature Reviews Drug Discovery, 2010
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologyThe Oncologist, 2009
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor ActivityClinical Cancer Research, 2009
- Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancersCancer Science, 2003
- Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancerOncogene, 1997